Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 14, 2014; 20(14): 3938-3949
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3938
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3938
Endoscopic submucosal dissection for undifferentiated-type early gastric cancer: Do we have enough data to support this?
Choong Nam Shim, Sang Kil Lee, Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, South Korea
Author contributions: Shim CN contributed to study concept and design, data collection, analysis, and drafting of the manuscript; Lee SK contributed to study concept and design, critical revision of the manuscript, and study supervision.
Correspondence to: Sang Kil Lee, MD, PhD, Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, South Korea. sklee@yuhs.ac
Telephone: +82-2-2228996 Fax: +82-2-3936884
Received: October 27, 2013
Revised: January 18, 2014
Accepted: February 17, 2014
Published online: April 14, 2014
Processing time: 168 Days and 12.4 Hours
Revised: January 18, 2014
Accepted: February 17, 2014
Published online: April 14, 2014
Processing time: 168 Days and 12.4 Hours
Core Tip
Core tip: Endoscopic submucosal dissection (ESD) for intramucosal undifferentiated (UD) type early gastric cancer (EGC) without ulceration and with diameter ≤ 2 cm is regarded as an investigational treatment according to the Japanese gastric cancer treatment guidelines. In contrast, the controversial results about the safety of ESD for UD-EGC fulfilling the criteria have been reported and a little is known about the long-term outcomes. Therefore, in this review, we focused on the safety and therapeutic efficacy of ESD for UD-EGC with reference to risks for lymph node metastasis within the proposed criteria as well as the short-term and long-term outcomes of ESD for UD-EGC.